Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 July 2021Next earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 6 min agoDividend
Analysts recommendations
Institutional Ownership
RNAZ Latest News
Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138.
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate.
Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced new preliminary data from its Phase 0 clinical trial with radiolabeled TTX-MC138 suggesting anti-tumor activity. New results from the patient dosed in this trial indicate that a microdose of radiolabeled TTX-MC138 resulted in significant inhibition of the drug candidate's molecular target, miRNA-10b, in the patient's blood.
TransCode Therapeutics (NASDAQ: RNAZ) shares are declining after the company announced its upcoming annual shareholder meeting on June 13, 2024 at 9:30 a.m Eastern Time.
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Friday after the oncology company announced plans for a public share offering. TransCode Therapeutics hasn't yet revealed details of the proposed public stock offering.
TransCode Therapeutics (NASDAQ: RNAZ ) stock is falling hard on Tuesday after the medical company announced a public share offering. According to a press release, TransCode Therapeutics is offering 15.7 million shares of RNAZ stock for 51 cents each.
TransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-hours equity raise. On the back of preclinical results the RNA oncology stock traded as high as $3.20 and closed at $2.55, from a starting price of 66 cents.
Enlivening a soft Monday session on Wall Street, TransCode Therapeutics (NASDAQ: RNAZ ) saw its shares drive up 300% earlier this morning before settling around 240% up in the early afternoon session. Catapulting sentiment was news that TransCode's lead therapeutic candidate, TTX-MC138, demonstrated encouraging pre-clinical results.
What type of business is TransCode Therapeutics?
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
What sector is TransCode Therapeutics in?
TransCode Therapeutics is in the Healthcare sector
What industry is TransCode Therapeutics in?
TransCode Therapeutics is in the Biotechnology industry
What country is TransCode Therapeutics from?
TransCode Therapeutics is headquartered in United States
When did TransCode Therapeutics go public?
TransCode Therapeutics initial public offering (IPO) was on 08 July 2021
What is TransCode Therapeutics website?
https://www.transcodetherapeutics.com
Is TransCode Therapeutics in the S&P 500?
No, TransCode Therapeutics is not included in the S&P 500 index
Is TransCode Therapeutics in the NASDAQ 100?
No, TransCode Therapeutics is not included in the NASDAQ 100 index
Is TransCode Therapeutics in the Dow Jones?
No, TransCode Therapeutics is not included in the Dow Jones index
When was TransCode Therapeutics the previous earnings report?
No data
When does TransCode Therapeutics earnings report?
Next earnings report date is not announced yet